Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
1-2 March 2023

16th Annual European Life Sciences CEO Forum

Hilton Zurich Airport Hotel

Zurich

Switzerland

22-25 February 2023

IASLC 2023 Targeted Therapies of Lung Cancer Meeting

Fairmont Miramar, Santa Monica

CA

United States

6-9 February 2023

BIO CEO & Investor Conference 2023

New York Marriot Marquis

NY

United States

6 February 2023

ORYZON to give updates on corporate progress in February-March

18 January 2023

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

24 January 2023

Invest Securities Biomed Forum 2023

Paris

France

9-12 January 2023

41st Annual J.P. Morgan Healthcare Conference

Westin St. Francis Hotel, San Francisco

CA

United States

9-11 January 2023

12th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel, San Francisco

CA

United States

8 January 2023

6th Sachs Annual Neuroscience Innovation Forum

Marine’s Memorial Club, San Francisco

CA

United States

5 January 2023

ORYZON to give updates on corporate progress in January

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Current page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel